These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25270710)

  • 1. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.
    Falivene S; Giugliano FM; Grimaldi AM; Di Franco R; Toledo D; Muto M; Cammarota F; Borzillo V; Ascierto PA; Muto P
    BMC Dermatol; 2014 Sep; 14():15. PubMed ID: 25270710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
    Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
    J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab in non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
    Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
    J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
    Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
    Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
    Valeriani M; Muni R; Osti MF; De Sanctis V; Minniti G; Ardito F; Maurizi Enrici R
    Radiol Med; 2012 Feb; 117(1):125-32. PubMed ID: 21892718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
    Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
    N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
    Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
    J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
    Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
    Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.
    Mesía R; Rueda A; Vera R; Lozano A; Medina JA; Aguiar D; Árias F; Triana G; Carles J; López-López R
    Ann Oncol; 2013 Feb; 24(2):448-453. PubMed ID: 23041591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J
    Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
    Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
    Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.
    Balermpas P; Hambek M; Seitz O; Rödel C; Weiss C
    Strahlenther Onkol; 2009 Dec; 185(12):775-81. PubMed ID: 20013086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
    Kim S; Eleff M; Nicolaou N
    Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases.
    Giacchero D; Barrière J; Benezery K; Guillot B; Dutriaux C; Mortier L; Lacour JP; Thyss A; Peyrade F
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):716-8. PubMed ID: 21831617
    [No Abstract]   [Full Text] [Related]  

  • 20. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
    Gaffney DC; Soyer HP; Simpson F
    Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.